THE RELATIONSHIP BETWEEN URINARY BROMOTYROSINE LEVELS AND MONTELUKAST, BECLOMETASONE/FORMOTEROL, AND COMBINATION THERAPY OVER 3 MONTHS IN ASTHMA PATIENTS AT HARUM MELATI CLINIC, PRINGSEWU

DIMAS , TREND PINAKA BALADIKA (2025) THE RELATIONSHIP BETWEEN URINARY BROMOTYROSINE LEVELS AND MONTELUKAST, BECLOMETASONE/FORMOTEROL, AND COMBINATION THERAPY OVER 3 MONTHS IN ASTHMA PATIENTS AT HARUM MELATI CLINIC, PRINGSEWU. Masters thesis, UNIVERSITAS LAMPUNG.

Preview	File PDF 1. ABSTRAK - Dimas Trend Pinaka Baladika.pdf Download (203Kb) | Preview
	File PDF 2. TESIS FULL - Dimas Trend Pinaka Baladika.pdf Restricted to Hanya staf Download (4081Kb) | Minta salinan
Preview	File PDF Tesis tanpa pembahasan Dimas Fixed - Dimas Trend Pinaka Baladika.pdf Download (4084Kb) | Preview

Abstrak (Berisi Bastraknya saja, Judul dan Nama Tidak Boleh di Masukan)

ABSTRACT Background: Urinary bromotyrosine holds promise as a biomarker for asthma due to its stability and the non-invasive nature of urine sample collection. In asthma management, leukotriene receptor antagonists (LTRA) are often used as an alternative first-line therapy following inhaled corticosteroids. Purpose: This research aims to explore the connection between urinary bromotyrosine levels and the effects of montelukast, beclometasone/formoterol, and combination therapy over a three-month duration. Methods: The study involved 82 participants aged 6–65 years, recruited from Harum Melati Clinic, Pringsewu, between May and December 2023. Spirometry, urine tests, and differential counts were performed before and after a 3-month therapy period. Patients were grouped by obstruction severity into mild (n = 66) and moderate-severe (n = 6) categories, along with a non-asthmatic control group (n = 10). Only 28 patients completed the follow-up evaluation after 3 months. These participants were divided into three treatment groups: montelukast (n = 14), beclometasone/formoterol (n = 5), and combination therapy (n = 9). Urinary bromotyrosine levels were analyzed using the 3-BrY ELISA Kit EU3112. Results: Urinary bromotyrosine levels were significantly higher in asthma patients compared to the control group (154.11 ng/ml vs. 11.87 ng/ml, p = 0.000). No significant changes were detected after montelukast therapy (104.24 ng/ml vs. 40.79 ng/ml, p = 0.433) or beclometasone/formoterol therapy (136.25 ng/ml vs. 33.20 ng/ml, p = 0.345). However, a significant decrease was observed in the combination therapy group (39.63 ng/ml vs. 11.13 ng/ml) (95% CI 3.90–42.43, p = 0.028). Conclusion: The findings indicate that asthma patients have significantly higher urinary bromotyrosine levels compared to non-asthmatic individuals. A notable reduction in these levels was observed after 3 months of combination therapy, highlighting its potential effectiveness. Keywords: asthma, urinary bromotyrosine, montelukast. ABSTRAK Latar Belakang : Bromotyrosine urin memiliki banyak keuntungan sebagai biomarker potensial penyakit asma mengingat stabilitasnya dan pengumpulan sampel urin yang bersifat non-invasif. Dalam manajemen tatalaksana asma leukotriene receptor antagonist (LTRA) merupakan obat alternatif lini pertama setelah kortikosteroid inhalasi. Tujuan : Penelitian ini bertujuan untuk mengetahui hubungan kadar bromotyrosine urin dengan terapi montelukast selama 3 bulan. Metode : Penelitian ini melibatkan 82 pasien berusia antara 6-65 tahun dari Klinik Harum Melati, Pringsewu dari bulan Mei – Desember 2023. Dilakukan uji spirometri, urin, differential count sebelum dan setelah terapi 3 bulan, diklasifikasikan derajat obstruksi ringan (n= 66) dan sedang-berat (n=6) serta pasien non-asma untuk kontrol (n= 10). Hanya 28 pasien yang datang untuk evaluasi setelah 3 bulan terapi. Pasien dibagi menjadi 3 kelompok, yaitu kelompok terapi montelukast (n=14), beclometason/formoterol (n=5), dan kombinasi montelukast dan beclometason/formoterol (n=9). Bromotyrosine urin dinilai dengan 3-BrY Elisa Kit EU3112. Hasil : Kadar bromotyrosine urin penderita asma secara bermakna lebih tinggi dibandingkan dengan kontrol (154.11 ng/ml vs 11,87 ng/ml, p= 0,000). Tidak terdapat perbedaan bermakna kadar bromotyrosine urin setelah terapi montelukast (104.24 ng/ml vs 40.79 ng/ml, p=0,433) dan setelah terapi beclometason/formoterol (136,25 ng/ml vs 33,20 ng/ml, p= 0,345. Terjadi penurunan kadar bromotyrosine urin yang bermakna pada kelompok setelah terapi kombinasi montelukast dan beclometasone/formoterol (39.63 ng/ml vs 11.13 ng/ml) (95% CI 3.90-42.43, p= 0.028). Kesimpulan : Hasil penelitian menunjukkan pasien asma memiliki kadar bromotyrosine urin jauh lebih tinggi dibandingkan dengan non-asma. Kadar bromotyrosine urin menurun secara bermakna setelah terapi kombinasi (montelukast dan beclometason/formoterol) selama 3 bulan. Kata Kunci : asma, bromotyrosine urin, montelukast.

Jenis Karya Akhir:	Tesis (Masters)
Subyek:	300 Ilmu sosial 600 Teknologi (ilmu terapan) > 610 Ilmu kedokteran, ilmu pengobatan dan ilmu kesehatan
Program Studi:	FAKULTAS KEDOKTERAN (FK) > Prodi S2-Pulmonologi Dan Kedokteran Respirasi
Pengguna Deposit:	A.Md Cahya Anima Putra .
Date Deposited:	07 Nov 2025 07:11
Terakhir diubah:	11 Nov 2025 06:37
URI:	http://digilib.unila.ac.id/id/eprint/92812

Actions (login required)

Lihat Karya Akhir